

## **AMENDMENTS TO THE SPECIFICATION**

Please insert the following heading and new paragraph on page one, line 2, between the title "ANTIDEPRESSANT DOSAGE FORM" and the heading "FIELD OF THE INVENTION":


### **-- CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is a Continuation Application of U.S. Patent Application Serial No. 08/442,292, filed May 16, 1995, which is a Divisional Application of U.S. Patent Application Serial No. 08/068,480 filed May 27, 1993, now U.S. Patent No. 6,440,457B1, both of which are incorporated herein by reference. --

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claim 1** (original): A therapeutic composition comprising 0.5 mg to 750 mg of a drug of the formula:




wherein the dotted line represents an unsaturation or a cycloalkenyl group; R<sub>1</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R<sub>2</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R<sub>4</sub> is a member selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, formyl, and alkanoyl of 2 to 7 carbon atoms; R<sub>5</sub> and R<sub>6</sub> are independently a member selected from the group consisting of hydrogen, hydroxyl and alkyl of 1 to 6 carbon atoms, an alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms in which each alkyl group comprises 1 to 6 carbon atoms, alkanamide of 2 to 7 carbon atoms, halo and trifluoroethyl; R<sub>7</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbons; and n is one of the integers 0, 1, 2, 3, and 4, and a pharmaceutically acceptable addition salt; and wherein the drug of the formula is blended with a poly(alkylene oxide) polymer.

**Claims 2-7 (canceled)**

**Claim 8 (new):** A controlled-release dosage form for the oral delivery of a drug to an environment of use, wherein the dosage form comprises:

- (a) a wall comprising at least in part a composition permeable to the passage of fluid, which wall surrounds;
- (b) a compartment;
- (c) a drug composition in the compartment comprising a drug of the formula:



wherein the dotted line represents a member selected from the group consisting of an unsaturation and cycloalkenyl group; R<sub>1</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R<sub>2</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms; R<sub>4</sub> is a member selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, formyl, and alkanoyl of 2 to 7 carbon atoms; R<sub>5</sub> and R<sub>6</sub> are independently a member selected from the group consisting of hydrogen, hydroxyl and alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyloxy of 2 to 7 carbon atoms, nitro, alkylmercapto of 1 to 6 carbon atoms, amino, alkylamino of 1 to 6 carbon atoms, alkanamide of 2 to 7 carbon atoms, halo and trifluoroethyl; R<sub>7</sub> is a member selected from the group consisting of hydrogen and alkyl of 1 to 6 carbons; and n is 0 to 4; and

- (d) a displacement in the compartment comprising a composition comprising an osmotically active compound; and,
- (e) an exit passageway in the dosage form for delivering the drug composition from the dosage form in a controlled-release manner.

**Claim 9 (new):** A controlled-release dosage form for the oral delivery of 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol to a patient, wherein the dosage form comprises:

- (a) a wall comprising a semipermeable composition permeable to the passage of fluid, which wall surrounds;
- (b) a compartment;
- (c) a therapeutic composition in the compartment comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol;
- (d) a displacement composition in the compartment comprising an osmotically effective compound; and
- (e) an exit passageway in the dosage form for delivering the 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form in a controlled-release manner.